Merck to buy Prometheus Biosciences for about $11 billion
Merck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies
Read More
Prometheus Biosciences Inc
Stocks are headed for their worst year since 2008, but some names doubled or more in 2022
The stocks that won big this year include tankers for petroleum products and energy firms. Source link
Read More